Vaccine Adjuvants Market

Vaccine Adjuvants Market by Types (Adjuvant Emulsion, Particulate, Combination, Pathogen, and Others), Routes of Administration (Intradermal, Intranasal, Intramuscular, Oral, and Others), Applications (Infectious Disease, Cancer, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2247
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 56
  • No. Of Pages: 165
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global vaccine adjuvants market size is estimated to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising incidences of cervical cancer and other infectious diseases such as tuberculosis, human papillomavirus, and HIV.

Adjuvants are immune supporters simultaneously with antigens in order to boost vaccine efficiency. Adjuvants need was established with vaccine after discovery of highly purified, safe but less synthetic antigens, synthetic antigens, immunogenic through innovation in recombinant DNA technology. Adjuvants affect the immune system in various ways: to modulate humoral responses, to increase the immunogenicity of weak antigens, to enhance speed of immune response, to stimulate cell-mediated immunity, and to improve induction of mucosal immunity. Additionally, increasing focus on the long term effect of immunization for existing diseases and newly found COVID-19 vaccine are expected to fuel demand for adjuvants. The need of adjuvant development of these innovative and effective products has increased due to the insufficient immunogenicity of vaccine antigens.

Vaccine Adjuvants Market Key Takeaways

Major players are actively engaged in the research and development of adjuvants to treat diseases. There are certain products that are under the clinical trials namely ISCOM & ISCOMMATRIX, AS01, AS02, and the potential development of these drugs are key aspects for the market growth. Moreover, one of the major dimension for the market can be the expansion of awareness campaigns from government agencies and organizations. For instance, a program was initiated by National Institute of Allergy and Infectious Diseases for adjuvants for human use.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising incidences of chronic diseases such as tuberculosis, human papillomavirus, HIV, and cervical cancer are expected to fuel the demand for adjuvants.
  • Increasing focus on the long term effect of immunization for existing diseases and newly found COVID-19 is expected to accelerate demand for adjuvants.
  • Growing use of synthetic vaccines and rising awareness of regular immunization for disease prevention are expected to boost the market growth in the coming years.
  • Favorable government initiatives and policies for encouraging the development of effective vaccine for the treatment of serious diseases is anticipated to spur the market revenue.

Scope of the Report                         

The report on the global vaccine adjuvants market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Vaccine Adjuvants Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Adjuvant Emulsion, Particulate, Combination, Pathogen, and Others), Routes of Administration (Intradermal, Intranasal, Intramuscular, Oral, and Others), and Applications (Infectious Disease, Cancer, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Novavax, Inc.; SPI Pharma, Inc.; Agenus, Inc.; Adjuvance Technologies, Inc; CSL Limited; InvivoGen; Brenntag Biosector; and GlaxoSmithKline plc.

Market Segment Insights

Particulate segment is expected to grow at a rapid pace

Based on types, the global vaccine adjuvants market is divided into adjuvant emulsion, particulate, combination, pathogen, and others. The particulate segment is expected to grow at a rapid pace of the market in the coming years as these are most commonly used adjuvants for hepatitis B and HPV vaccines. However, the pathogen segment is anticipated to account for a key market share during the forecast period as this is cost-effective and easily available in the market.

Vaccine Adjuvants Market By Types

Intramuscular segment is projected to expand at a considerable CAGR

On the basis of routes of administration, the market is segregated into intradermal, intranasal, intramuscular, oral, and others. The intramuscular segment is projected to expand at a considerable CAGR during the projected period due to the high efficiency of these to support vaccines. Meanwhile, the intradermal segment is anticipated to hold a large market share during the forecast period owing to longer absorption and duration of action as compared to other adjuvants.

Infectious disease segment is expected to register a robust growth rate

Based on applications, the global vaccine adjuvants market is divided into infectious disease, cancer, and others. The infectious disease segment accounted for a key share of the market in 2020 and is expected to register a robust growth rate in the coming years owing to large pipeline of products. On the other hand, the cancer segment is anticipated to grow significantly during the forecast period due to high number of incidences and ongoing research and development activities for targeted therapy.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market during the projected period owing to rise in investments in research and development activities and in fatal diseases in the region. The market of Asia Pacific, however, is expected to exhibit a considerable growth rate during the forecast period due to improving healthcare facilities and availability of medicines in the region.

Vaccine Adjuvants Market By Regions

Segments

Segments Covered in the Report
The global vaccine adjuvants market has been segmented on the basis of

Types
  • Adjuvant Emulsion
  • Particulate
  • Combination
  • Pathogen
  • Others
Routes of Administration
  • Intradermal
  • Intranasal
  • Intramuscular
  • Oral
  • Others
Applications
  • Infectious Disease
  • Cancer
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Novavax, Inc.
  • SPI Pharma, Inc.
  • Agenus, Inc.
  • Adjuvance Technologies, Inc.
  • CSL Limited
  • InvivoGen
  • Brenntag Biosector
  • GlaxoSmithKline plc.

Competitive Landscape

Key players competing in the global vaccine adjuvants market are Novavax, Inc.; SPI Pharma, Inc.; Agenus, Inc.; Adjuvance Technologies, Inc; CSL Limited; InvivoGen; Brenntag Biosector; and GlaxoSmithKline plc. The main market players are continuously engaged in the business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations. For instance, GSK collaborated with Exscientia.ai for developing new drugs in July 2017.

Vaccine Adjuvants Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vaccine Adjuvants Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Vaccine Adjuvants Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Vaccine Adjuvants Market - Supply Chain
  4.5. Global Vaccine Adjuvants Market Forecast
     4.5.1. Vaccine Adjuvants Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Vaccine Adjuvants Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Vaccine Adjuvants Market Absolute $ Opportunity
5. Global Vaccine Adjuvants Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Vaccine Adjuvants Market Size and Volume Forecast by Types
     5.3.1. Adjuvant Emulsion Particulate Combination Pathogen Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Vaccine Adjuvants Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Vaccine Adjuvants Market Size and Volume Forecast by Applications
     6.3.1. Infectious Disease Cancer Others
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Vaccine Adjuvants Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Vaccine Adjuvants Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Vaccine Adjuvants Demand Share Forecast, 2019-2026
8. North America Vaccine Adjuvants Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Vaccine Adjuvants Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Vaccine Adjuvants Market Size and Volume Forecast by Types
     8.4.1. Adjuvant Emulsion Particulate Combination Pathogen Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Vaccine Adjuvants Market Size and Volume Forecast by Applications
     8.7.1. Infectious Disease Cancer Others
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Vaccine Adjuvants Demand Share Forecast, 2019-2026
9. Latin America Vaccine Adjuvants Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Vaccine Adjuvants Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Vaccine Adjuvants Market Size and Volume Forecast by Types
     9.4.1. Adjuvant Emulsion Particulate Combination Pathogen Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Vaccine Adjuvants Market Size and Volume Forecast by Applications
     9.7.1. Infectious Disease Cancer Others
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Vaccine Adjuvants Demand Share Forecast, 2019-2026
10. Europe Vaccine Adjuvants Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Vaccine Adjuvants Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Vaccine Adjuvants Market Size and Volume Forecast by Types
     10.4.1. Adjuvant Emulsion Particulate Combination Pathogen Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Vaccine Adjuvants Market Size and Volume Forecast by Applications
     10.7.1. Infectious Disease Cancer Others
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Vaccine Adjuvants Demand Share Forecast, 2019-2026
11. Asia Pacific Vaccine Adjuvants Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Vaccine Adjuvants Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Vaccine Adjuvants Market Size and Volume Forecast by Types
     11.4.1. Adjuvant Emulsion Particulate Combination Pathogen Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Vaccine Adjuvants Market Size and Volume Forecast by Applications
     11.7.1. Infectious Disease Cancer Others
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Vaccine Adjuvants Demand Share Forecast, 2019-2026
12. Middle East & Africa Vaccine Adjuvants Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Vaccine Adjuvants Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Vaccine Adjuvants Market Size and Volume Forecast by Types
     12.4.1. Adjuvant Emulsion Particulate Combination Pathogen Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Vaccine Adjuvants Market Size and Volume Forecast by Applications
     12.7.1. Infectious Disease Cancer Others
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Vaccine Adjuvants Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Vaccine Adjuvants Market: Market Share Analysis
  13.2. Vaccine Adjuvants Distributors and Customers
  13.3. Vaccine Adjuvants Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Novavax, Inc. SPI Pharma, Inc. Agenus, Inc. Adjuvance Technologies, Inc. CSL Limited InvivoGen  
Segments Covered in the Report
The global vaccine adjuvants market has been segmented on the basis of

Types
  • Adjuvant Emulsion
  • Particulate
  • Combination
  • Pathogen
  • Others
Routes of Administration
  • Intradermal
  • Intranasal
  • Intramuscular
  • Oral
  • Others
Applications
  • Infectious Disease
  • Cancer
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Novavax, Inc.
  • SPI Pharma, Inc.
  • Agenus, Inc.
  • Adjuvance Technologies, Inc.
  • CSL Limited
  • InvivoGen
  • Brenntag Biosector
  • GlaxoSmithKline plc.

Key players competing in the global vaccine adjuvants market are Novavax, Inc.; SPI Pharma, Inc.; Agenus, Inc.; Adjuvance Technologies, Inc; CSL Limited; InvivoGen; Brenntag Biosector; and GlaxoSmithKline plc. The main market players are continuously engaged in the business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations. For instance, GSK collaborated with Exscientia.ai for developing new drugs in July 2017.

Vaccine Adjuvants Market By Key Players

Buy Report